Bree Foster Arrowhead's RNAi drug cuts triglycerides by up to 81 percent and eliminates pancreatitis risk in highest-risk patients Arrowhead Pharmaceuticals announced positive topline results this week from two global Phase 3 trials SHASTA-3 and SHASTA-4 of plozasiran, an RNA interference (RNAi) therapy that silences apolipoprotein C-III (APOC3), a liver-produced protein that drives triglyceride accumulation
That can often mean fewer side effects, better results, and a much higher chance the patient will stay on the medication long enough to see real, lasting change.- Dr
Gender-Specific Adjustments Men often tolerate 200300 mcg/day as part of a hypertrophy or recovery program
Lifestyle change (diet and exercise) alone produces modest weight loss and then fails to hold for most people, even when the program, the coaching, and the personal effort continue
This is particularly relevant in primary care settings but also extends to specialties dealing with MASLD-related multimorbidity, such as cardiology, endocrinology/diabetology, internal medicine, and specialists in lipid disorders, obesity, and cardiovascular medicine
A standard insulin syringe measures medication in units, where 100 units equals 1 mL
